Today's News | Note: News feeds may no longer be available for the articles on this page.

Synta gets $10 million cancer drug payment 12:02 PM 2/17/2009
Boston Globe - United States
Synta Pharmaceuticals Corp received a $10 million payment from GlaxoSmithKline for development work on cancer drug elesclomol as a treatment for late-stage melanoma and prostate cancer. ...

Global forex volatility to continue in 2009 -Teva CFO 5:06 AM 2/17/2009
Reuters - USA
Teva Pharmaceutical Industries said that global exchange rate volatility impacted its 2008 earnings and looks to continue in 2009. ...

NeuroSearch inks development deal with Lilly 4:46 AM 2/17/2009
Reuters - USA
NeuroSearch has signed a three-year drug discovery and development deal with Eli Lilly and Co to investigate methods for treating central nervous system disorders. ...

Biotech excited about hair-growth results 3:36 AM 2/17/2009
San Diego Union Tribune - San Diego,CA,USA
Biotechnology company Histogen is unveiling preliminary results from an early-stage clinical trial that showed experimental hair regrowth therapy ReGenica increased new hair growth and the thickness of existing hair in men after 3 months. ...

Ark's Cerepro drug gets "named patient" approval 7:28 AM 2/16/2009
Reuters - USA
Ark Therapeutics said its lead drug Cerepro was made available to a patient outside a clinical trial for the first time. The French requested that the brain cancer drug be made available on a named patient basis. ...

Bad Memories Fade as Drug Blunts Recall of Spiders 6:26 AM 2/16/2009
Bloomberg - USA
Propranolol may stop frightening images or experiences from lodging in the memory and resurfacing to cause fear and anxiety. The study measured how people reacted when shown pictures of spiders. It has shown promise preventing post-traumatic stress disorder (PTSD). ...

GSK shares research to help poor countries 6:00 AM 2/15/2009
ABC Online - Australia
GlaxoSmithKline has launched an initiative aimed at stimulating research into neglected tropical diseases including cholera, malaria, and leprosy. ...

Takeda Wins US Approval for First New Gout Drug in 40 Years 7:40 AM 2/14/2009
Bloomberg - USA
The US FDA approved Takeda Pharmaceutical Co's Uloric (febuxostat) to control excess uric acid in the blood. ...

Savient Slips And Falls On Gout Drug Delay 12:45 PM 2/13/2009
Forbes - NY,USA
The US FDA needs more time to review Savient Pharmaceuticals' application for Krystexxa, a gout drug candidate. ...

Novartis unit gets European OK for biosimilar 10:45 AM 2/13/2009
Forbes - NY,USA
Novartis AG's drug unit Sandoz received European regulatory approval for a version of the biotechnology drug Neupogen (filgrastim). ...

Onyx Pharmaceuticals updates cancer drug trials 7:55 AM 2/13/2009
Forbes - NY,USA
Onyx Pharmaceuticals Inc plans to provide an update to the US FDA covering Nexavar which is currently approved for treating liver and kidney cancer. Trials are under way to determine effectiveness to treat lung cancer, melanoma, breast cancer, and others. ...

Boehringer decision may cost Inspire Pharmaceuticals 4:30 PM 2/12/2009
Bizjournals.com - Charlotte,NC,USA
Inspire co-promotes the allergic conjunctivitis treatment Elestat with Allergan which licenses the patent from Boehringer Ingelheim. Boehringer decided not to file suit in response to three drugmakers’ applications to sell generics. ...

Teva, Active Biotech get special review on drug 12:09 PM 2/12/2009
Forbes - NY,USA
Teva Pharmaceutical Industries' oral treatment candidate laquinimod for multiple sclerosis will receive a fast track review from the US FDA. ...

La Jolla stops developing lupus drug, shares tank 9:32 AM 2/12/2009
Reuters - USA
La Jolla Pharmaceutical Co stops development of experimental treatment Riquent for lupus after an interim efficacy analysis showed negative results. ...

Merck to pay $130 mln to Insmed in biologics deal 7:11 AM 2/12/2009
Reuters - USA
Merck & Co will pay $130 million to acquire experimental biologic medicines from Insmed Inc. It will also get the company's manufacturing plant as the drugmaker pushes into biotech and generic biotech drugs. ...

Osiris' stem-cell drug for heart attack proves safe 6:21 AM 2/12/2009
Reuters - USA
Osiris Therapeutics Inc's early stage trial of its experimental stem-cell treatment Prochymal for heart attacks showed the drug was safe. It improved heart function in patients. ...

<- Day Earlier | Today's News